for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adocia SAS

ADOC.PA

Latest Trade

11.32EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

10.06

 - 

22.60

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
11.32
Open
--
Volume
--
3M AVG Volume
0.81
Today's High
--
Today's Low
--
52 Week High
22.60
52 Week Low
10.06
Shares Out (MIL)
6.92
Market Cap (MIL)
78.55
Forward P/E
-87.08
Dividend (Yield %)
--

Next Event

Adocia SA Annual Shareholders Meeting

Latest Developments

More

Eli Lilly Says Arbitration Panel Rules In Favor Of Co In Complaint Filed By Adocia

Adocia H1 Net Income Loss of EUR 13.0 Million

Adocia Initiates 3-Week Phase 1B Study Of ADO09

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Adocia SAS

Adocia SA, also known as Adocia, is a France-based company engaged in the biotechnology business sector. It specializes in the research and development of biotherapy products used in tissue regeneration and for treating chronic diseases. The Company develops a BioChaperone Platform used for therapeutic protein delivery in regenerative medicine and chronic disease areas, such as wound Healing, diabetes, ulcers and monoclonal antibody creation. The Company completed two Phases I and II studies of the formulation of human insulin, two Phases I and II studies of insulin lispro and one Phase I/II on a combination of insulin glargine, the basal insulin and insulin lispro, an insulin analog. Adocia also undertaken the activities in the field of formulation of monoclonal antibodies which are molecules for the treatment of various chronic pathologies (oncology, inflammation, etc.).

Industry

Biotechnology & Drugs

Contact Info

115 avenue Lacassagne

+33.4.72610610

https://www.adocia.com/

Executive Leadership

Gerard Soula

Chairman of the Board, Chief Executive Officer

Olivier Soula

Deputy Chief Executive Officer, Vice President - Research & Development, Director

Valerie Danaguezian

Chief Financial Officer, Administrative Director

You-Ping Chan

Scientific Director

Remi Soula

Business Development and Intellectual Property Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-1.150

2017

-1.200

2018

1.000

2019(E)

-0.130
Price To Earnings (TTM)
10.28
Price To Sales (TTM)
1.66
Price To Book (MRQ)
1.71
Price To Cash Flow (TTM)
9.08
Total Debt To Equity (MRQ)
15.10
LT Debt To Equity (MRQ)
10.67
Return on Investment (TTM)
15.22
Return on Equity (TTM)
12.30

Latest News

BRIEF-Tonghua Dongbao Pharmaceutical Signs Agreements With SA Adocia On Insulin-Related Products

* SAYS IT SIGNS AGREEMENTS WITH SA ADOCIA ON INSULIN RELATED PRODUCTS Source text in Chinese: https://bit.ly/2Kh2DtQ Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Adocia And Tonghua Dongbao Announce A Strategic Alliance For Biochaperone Combo And Biochaperone Lispro In China

* ADOCIA AND TONGHUA DONGBAO ANNOUNCE A STRATEGIC ALLIANCE FOR BIOCHAPERONE(®) COMBO AND BIOCHAPERONE(®) LISPRO IN CHINA

BRIEF-Adocia Starts First-In-Human Clinical Study Of BioChaperone Pramlintide Insulin

* ADOCIA INITIATES FIRST-IN-HUMAN CLINICAL STUDY OF BIOCHAPERONE® PRAMLINTIDE INSULIN IN PEOPLE WITH TYPE 1 DIABETES

BRIEF-Adocia Had Cash And Cash Equivalents Of EUR 27.6 Million On March 31

* ADOCIA ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS: CASH POSITION AND REVENUE

BRIEF-Adocia FY Operating Revenue Down At 27.2 Million Euros

* CASH POSITION OF APPROXIMATELY EUR 35 MILLION ON DECEMBER 31(ST), 2017

BRIEF-Adocia Files Additional Arbitration Claims Against Eli Lilly & Company​

* ADOCIA FILES ADDITIONAL ARBITRATION CLAIMS AGAINST ELI LILLY & COMPANY

BRIEF-Adocia Announces Positive Topline Data From Study Of Biochaperone®

* ADOCIA ANNOUNCES POSITIVE TOPLINE DATA FROM A DOSE-PROPORTIONALITY STUDY OF BIOCHAPERONE® COMBO IN PEOPLE WITH TYPE 2 DIABETES

BRIEF-Adocia Announces Expanded Biochaperone Product Portfolio Beyond Diabetes

* ADOCIA ANNOUNCES EXPANDED BIOCHAPERONE® PRODUCT PORTFOLIO BEYOND DIABETES

BRIEF-Adocia Announces Positive Topline Study Results

* ADOCIA ANNOUNCES POSITIVE TOPLINE STUDY RESULTS COMPARING ULTRA-RAPID INSULIN BIOCHAPERONE LISPRO WITH NOVOLOG AND FIASP IN PEOPLE WITH TYPE 1 DIABETES

BRIEF-Adocia reports topline results of Biochaperone Glucagon Phase 1 study

* ADOCIA REPORTS TOPLINE RESULTS OF BIOCHAPERONE® GLUCAGON PHASE 1 STUDY

BRIEF-Adocia appoints Dr. Stanislav Glezer as Chief Medical Officer

* ADOCIA ANNOUNCES APPOINTMENT OF DR. STANISLAV GLEZER AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Adocia H1 net result turns to profit of 7.1 million euros

* CASH POSITION OF € 52.3 MILLION AT THE END OF JUNE 30, 2017

BRIEF-Adocia initiates phase 1b clinical study on dose-proportionality of Biochaperone combo

* ADOCIA INITIATES A PHASE 1B CLINICAL STUDY ON THE DOSE-PROPORTIONALITY OF BIOCHAPERONE COMBO IN PEOPLE WITH TYPE 2 DIABETES

BRIEF-Adocia initiates study comparing BioChaperone Lispro U100 with Fiasp and Novolog

* ADOCIA INITIATES A STUDY COMPARING ULTRA-RAPID INSULIN BIOCHAPERONE LISPRO U100 WITH FIASP AND NOVOLOG ADMINISTERED WITH AN INSULIN PUMP

BRIEF-Adocia launches first-in-man clinical study of BioChaperone Glucagon

* LAUNCHES FIRST-IN-MAN CLINICAL STUDY OF BIOCHAPERONE GLUCAGON

BRIEF-Adocia Q1 revenue rises to 19.4 million euros

* Cash position of 52 million euros ($55.34 million) at March 31, 2017

BRIEF-Adocia FY net result turns to loss of 7.9 million euros

* FY net loss 7.9 million euros ($8.36 million) versus profit 12.6 million euros year ago

BRIEF-Adocia 2016 revenue down at 22.4 million euros

* 2016 revenue of 22.4 million euros ($23.7 million), compared to 36.9 million euros in 2015

BRIEF-Adocia, given its cash position, clarifies that no capital increase is being considered

* Given its 58 million euros ($62.2 million) cash position at beginning of 2017 and current market conditions, Adocia would like to clarify that no capital increase is being considered Source text for Eikon: Further company coverage: ($1 = 0.9327 euros) (Gdynia Newsroom)

BRIEF-Adocia Q3 revenue rises to 6.5 million euros

* Revenue of 6.5 million euros for Q3, compared to 6.2 million euros in 2015

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up